Managing diabetic macular edema: The leading cause of diabetes blindness, World Journal of Diabetes, vol.2, issue.6, pp.98-104, 2011. ,
DOI : 10.4239/wjd.v2.i6.98
Global Prevalence and Major Risk Factors of Diabetic Retinopathy, Diabetes Care, vol.35, issue.3, pp.556-564, 2012. ,
DOI : 10.2337/dc11-1909
Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population, Diabetes & Metabolism, vol.35, issue.6, pp.431-438, 2009. ,
DOI : 10.1016/j.diabet.2009.06.002
URL : https://hal.archives-ouvertes.fr/inserm-00394359
Ranibizumab for Diabetic Macular Edema, Ophthalmology, vol.119, issue.4, pp.789-801, 2012. ,
DOI : 10.1016/j.ophtha.2011.12.039
Intravitreal Aflibercept for Diabetic Macular Edema, Ophthalmology, vol.121, issue.11, pp.2247-2254, 2014. ,
DOI : 10.1016/j.ophtha.2014.05.006
Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting, Ophthalmologica, vol.236, issue.4, pp.207-214, 2016. ,
DOI : 10.1159/000453006
Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.10, pp.1904-1914, 2014. ,
DOI : 10.1016/j.ophtha.2014.04.024
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema, American Journal of Ophthalmology, vol.164, pp.118-127, 2016. ,
DOI : 10.1016/j.ajo.2015.12.030
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab, Ophthalmic Surgery, Lasers and Imaging Retina, vol.46, issue.9, pp.950-954, 2015. ,
DOI : 10.3928/23258160-20151008-08
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab, Clinical Ophthalmology, vol.9, pp.1715-1718, 2015. ,
DOI : 10.2147/OPTH.S81523
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, vol.28, issue.281, pp.171-185, 2012. ,
DOI : 10.1200/JCO.2009.24.8252
Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials, Clinical Ophthalmology, vol.10, pp.1103-1110, 2016. ,
DOI : 10.2147/OPTH.S100764
Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy, Archivos de la Sociedad Espa??ola de Oftalmolog??a (English Edition), vol.90, issue.10, pp.475-480, 2015. ,
DOI : 10.1016/j.oftale.2015.10.019
INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA, Retina, vol.35, issue.7, pp.1429-1435, 2015. ,
DOI : 10.1097/IAE.0000000000000490
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema, Clinical Ophthalmology, vol.7, pp.1423-1428, 2013. ,
DOI : 10.2147/OPTH.S48364
Intravitreal Aflibercept for Diabetic Macular??Edema, Ophthalmology, vol.122, issue.10, pp.2044-2052, 2015. ,
DOI : 10.1016/j.ophtha.2015.06.017
Effect of aflibercept in insufficient responders to prior anti- VEGF therapy in neovascular AMD, " Graefe's Archive for, Clinical and Experimental Ophthalmology, vol.252, pp.1705-1709, 2014. ,
Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis, Acta Ophthalmologica, vol.115, issue.2, pp.206-207, 2011. ,
DOI : 10.1016/j.ophtha.2008.07.007